For low-performing clinical trial sites, choose revision not rejection
If organizations are concerned about a low-performing site, changes should be made. But that doesn't mean the sites need to be cut.
Melissa Easy
DrugDev was born when Melissa “Liss” Easy saw the inefficiency of matching clinical trial investigators to the right protocols. Today she leads DrugDev’s site start-up activities, bringing pharma and investigators together with technology, service, and more open communication. Liss can be reached at [email protected]